Ipamorelin
Selective pentapeptide GH secretagogue studied in GHSR-1a signaling, pulsatile growth hormone release, sleep-related GH secretion, and preclinical bone-growth research.
$80.00
- FormatLyophilized Powder / 10 mg
- Storage-20°C for up to 24 months
50 in stock
About Ipamorelin
Ipamorelin is a synthetic five-amino-acid peptide that acts as a selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a). Preclinical research has examined its concentration-dependent stimulation of growth hormone release, preservation of pulsatile GH secretion, and selectivity relative to older GH secretagogues. Studies have also investigated Ipamorelin in relation to cortisol, ACTH, and prolactin signaling, nocturnal GH secretion, bone-growth models, and combination research with GHRH analogs.
Full Specification
| Molecular Formula | C38H49N9O5 |
| Molecular Weight | 711.85 g/mol |
| Purity | ≥99% (HPLC verified) |
| Appearance | White Lyophilized Powder |
| Storage | -20°C for up to 24 months |
| Format | Lyophilized Powder / 10 mg |
The Ipamorelin Molecule
An illustrative representation generated from the compound's molecular formula, alongside its logged molecular data. This figure is schematic — not a measured conformation.
How Ipamorelin Works
The pathways Ipamorelin acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Ghrelin Receptor Activation
GHSR-1a AgonistIpamorelin selectively binds the Growth Hormone Secretagogue Receptor 1a (GHSR-1a) on anterior pituitary somatotrophs, producing concentration-dependent growth hormone release.
Pituitary Selectivity
Low Off-Target Hormone ActivityResearch characterizes Ipamorelin as a selective GH secretagogue with no significant ACTH, cortisol, or prolactin elevation at concentrations producing substantial GH release.
Physiologic GH Secretion Pattern
Pulsatile GH ReleaseIpamorelin has been studied for discrete pulsatile growth hormone release, with peak GH measured at approximately 40 minutes post-dose and additive effects reported when combined with GHRH analogs.
What Ipamorelin Is Researched For
Selective GH Secretagogue
Studied as a selective growth hormone secretagogue through GHSR-1a activation, with GH release measured without accompanying cortisol, ACTH, or prolactin elevation in characterized models.
GH Secretion & Sleep
Studied in human research populations through measurement of growth hormone during early nocturnal sleep phases and comparison with cortisol responses.
Bone Growth Models
Studied in rat models using dose-dependent bone growth as a downstream endpoint of GH-axis activation.
Synergy with GHRH Analogs
Studied alongside GHRH analogs such as CJC-1295 to investigate complementary receptor pathways and effects on GH pulse amplitude.
Study-Reported Magnitudes
Representative figures from published research; results vary by protocol.
Common Questions About Ipamorelin
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the GHSR-1a receptor. Research has measured concentration-dependent growth hormone release following receptor activation.
Ipamorelin is characterized by a higher degree of selectivity for growth hormone release. The supplied source reports that it does not significantly elevate ACTH, cortisol, or prolactin at concentrations that produce substantial GH release, unlike the broader activity associated with older secretagogues such as GHRP-6.
Research has examined Ipamorelin through growth hormone release, pulsatile GH secretion, hormone selectivity, sleep-related GH secretion, and bone-growth endpoints in preclinical and human research models.
Ipamorelin acts through the GHSR-1a receptor, while GHRH analogs such as CJC-1295 act through the GHRH receptor. Combination research therefore examines complementary signaling pathways and their effects on growth hormone pulse amplitude.
The supplied source does not state that Ipamorelin is FDA approved. This material is supplied for research use only and is not presented as an approved pharmaceutical product.
The supplied specification recommends storage at -20°C for up to 24 months.